Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Exclusion Criteria

• •1）Dual or multiple primary NSCLC
• •2）Any prior anti-tumor treatment
• •3）With history of other malignancy except for radical resected tumors without recurrence for 5 years or more
• •4）History of interstitial lung disease or with relative risk factors
• •5）Diseases or clinical states with severe abnormalities of gastrointestinal function that may interfere with the ingestion, transit, or absorption of the study drug.e.g., inability to take medication orally, uncontrolled nausea and vomiting
• •6）Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrolment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrolment
• •7）With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment
• •8）Prolongation of ECG QTc or with relative risk factors
• •9）psychopath and/or mental illness
• •10）Pre-existing or coexisting bleeding disorders
• •11）Women with pregnancy or breastfeeding
• •12）Allergic to study drugs or any component
• •13）Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate